FierceBiotech Dec 20, 2025 Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
FierceBiotech Dec 19, 2025 Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners
FierceBiotech Dec 19, 2025 Galapagos ends turbulent year with mixed results for last remaining immunology asset
FierceBiotech Dec 18, 2025 Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
FierceBiotech Dec 18, 2025 Verge Genomics drops sole clinical candidate in return to AI drug discovery roots
FierceBiotech Dec 18, 2025 Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success
FierceBiotech Dec 18, 2025 After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3
FierceBiotech Dec 18, 2025 Lindus Health and Quotient team up to create one-stop shop for early to mid-stage trials